➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Boehringer Ingelheim
Harvard Business School
Merck
Mallinckrodt

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LANOXIN PEDIATRIC

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lanoxin Pediatric

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Duke Clinical Research Institute N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed St. Jude Medical N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00578617 Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial Completed Mayo Clinic N/A 2006-09-01 The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.
NCT00831506 Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects Completed Medivation, Inc. Phase 1 2009-02-01 This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lanoxin Pediatric

Condition Name

Condition Name for Lanoxin Pediatric
Intervention Trials
Healthy 5
Diabetes 1
Atrial Fibrillation 1
Pancreas Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lanoxin Pediatric
Intervention Trials
Pancreatic Neoplasms 1
Adenocarcinoma 1
Melanoma 1
Huntington Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lanoxin Pediatric

Trials by Country

Trials by Country for Lanoxin Pediatric
Location Trials
United States 15
Belgium 1
Sweden 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lanoxin Pediatric
Location Trials
Texas 2
California 2
Arizona 1
Connecticut 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lanoxin Pediatric

Clinical Trial Phase

Clinical Trial Phase for Lanoxin Pediatric
Clinical Trial Phase Trials
Phase 2 1
Phase 1 7
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lanoxin Pediatric
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lanoxin Pediatric

Sponsor Name

Sponsor Name for Lanoxin Pediatric
Sponsor Trials
Society of Family Planning 1
National Cancer Institute (NCI) 1
Alexion Pharmaceuticals 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lanoxin Pediatric
Sponsor Trials
Industry 11
Other 6
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Merck
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.